Advances in diagnostic and treatment options in patients with fibromyalgia syndrome

Open Access Rheumatology: Research and Reviews

Volumn 1, Issue 1, 2009, Pages 193-209

  Gur, Ali ^a   Oktayoglu, Pelin ^b  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Batman Regional Government Hospital   (Turkey)

Author keywords

Diagnosis; Fibromyalgia; Rehabilitation; Treatment

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABINOID; CITALOPRAM; CYCLOBENZAPRINE; DULOXETINE; FLUOXETINE; GABAPENTIN; HARKOSERIDE; KETAMINE; MEMANTINE; MILNACIPRAN; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NABILONE; OLANZAPINE; OXYBATE SODIUM; PRAMIPEXOLE; PREGABALIN; REBOXETINE; SIBUTRAMINE; SODIUM CHANNEL BLOCKING AGENT; TEGASEROD; TROPISETRON; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE; ZONISAMIDE;

ACUPUNCTURE; BLADDER IRRITATION; CHIROPRACTIC; CHRONIC DAILY HEADACHE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIZZINESS; EXERCISE; FATIGUE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEADACHE; HUMAN; HYPERBARIC OXYGEN; IRRITABLE COLON; LOW LEVEL LASER THERAPY; MAGNETOTHERAPY; MOOD DISORDER; MORNING STIFFNESS; MUSCLE RIGIDITY; NAUSEA; OSTEOPATHIC MEDICINE; PHYSIOTHERAPY; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SOMNOLENCE; TREMOR;

EID: 77953423505     PISSN: None     EISSN: 1179156X     Source Type: Journal    
DOI: 10.2147/oarrr.s8040     Document Type: Review

References (189)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
2. Yunus M, Masi A, Aldag J. A controlled study of primary fibromyalgia syndrome: clinical features and associations with other functional syndromes. J Rheumatol. 1989;16(Suppl 19):62-71.
3. Fitzcharles MA, Boulos P. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. Rheumatology (Oxford). 2003;42:263-267.
4. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol. 2003;17:685-701.
5. Mease PJ, Arnold LM, Crofford LJ, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient delphi exercises. Arthritis Rheum. 2008;59:952-960.
6. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19-28.
7. Buskila D, Pres J. Neuroendocrine mechanisms in fibromyalgia-chronic fatigue. Best Pract Res Clin Rheumatol. 2001;15(5):747-758.
8. Adler GK, Geenen R. Hypothalamic-pituitary-adrenal and autonomic nervous system functioning in fibromyalgia. Rheum Dis Clin N Am. 2005;31:187-202.
9. Weigent DA, Bradley LA, Blalock JE, Alarcon GS. Current concepts in the pathophysiology of abnormal pain perception in fibromyalgia. Am J Med Sci. 1998;315(6):405-412.
10. Henriksson KG. Fibromyalgia-from syndrome to disease. Overview of pathogenetic mechanisms. J Rehabil Med. 2003;(Suppl 41):89-94.
11. Buskila D, Pres J. Neuroendocrine mechanisms in fibromyalgia-chronic fatigue. Best Pract Res Clin Rheumatol. 2001;15(5):747-758.
12. Sörensen J, Graven-Nielsen T, Henriksson KG, Bengtsson M, Arendt-Nielsen L. Hiperexcitability in fibromyalgia. J Rheumatol. 1998;25: 152-155.
13. Staud R. Fibromyalgia pain: do we know the source? Curr Opin Rheumatol. 2004;16(2):157-163.
14. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (windup) in patients with fibromyalgia syndrome. Pain. 2001;91:165-167.
15. Staud R, Cannon RC, Mauderli AP, Robinson ME, Price DD, Vierck CJ Jr. Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome. Pain. 2003;102:87-95.
16. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain. 2002;99:49-59.
17. Gur A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment. Curr Pharm Des. 2008;14(13):1274-1294.
18. Harden RN, Revivo G, Song S, et al. A critical analysis of the tender points in fibromyalgia. Pain Med. 2007;8(2):147-156.
19. Williams DA, Gracely RH. Biology and therapy of fibromyalgia. Functional magnetic resonance imaging findings in fibromyalgia. Arthritis Res Ther. 2006;8:224.
20. Tunks E, Crook J, Norman G, Kalaher S. Tender points in fibromyalgia. Pain. 1988;34:11-19.
21. Bohr T. Problems with myofascial pain syndrome and fibromyalgia syndrome. Neurology. 1996;46:593-597.
22. Cohen M, Quintner J. Fibromyalgia syndrome, a problem of tautology. Lancet. 1993;342:906-909.
23. Tunks E, McCain GA, Hart LE, et al. The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and controls. J Rheumatol. 1995;22:944-952.
24. McCarthy DJ Jr, Gatter RA, Phelps P. A dolorimeter for quantification of articular tenderness. Arthritis Rheum. 1965;8:551-559.
25. Fischer AA. Pressure algometry over normal muscles. Standard values, validity and reproducibility of pressure threshold. Pain. 1987;30: 115-126.
26. McVeigh JG, Finch MB, Hurley DA, Basford JR, Sim J, Baxter GD. Tender point count and total myalgic score in fibromyalgia: changes over a 28 day period. Rheumatol Int. 2007;27:1011-1018.
27. Wilke SW. New developments in the diagnosis of f ibromyalgia syndrome: Say goodbye to tender points? Cleve Clin J Med. 2009;76(6):345-352.
28. Katz RS, Wolfe F, Michaud K. Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum. 2006;54(1):169-176.
29. Harris RE, Clauw DJ. Newer treatments for fibromyalgia syndrome. Ther Clin Risk Manag. 2008;4(6):1331-1342.
30. Gracely RH, Petzke F, Wolf JM, et al. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333-1343.
31. Lutz J, Jäger L, de Quervain D, et al. White and gray matter abnormalities in the brain of patients with fibromyalgia: a diffusion-tensor and volumetric imaging study. Arthritis Rheum. 2008;58(12):3960-3969.
32. Petrou M, Harris RE, Foerster BR, et al. Proton MR spectroscopy in the evaluation of cerebral metabolism in patients with fibromyalgia: comparison with healthy controls and correlation with symptom severity. Am J Neuroradiol. 2008;29(5):913-918.
33. Mountz JM, Bradley LA, Modell JG, et al. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum. 1995;38:926-938.
34. Kwiatek R, Barnden L, Tedman R, et al. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum. 2000;43:2823-2833.
35. Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ. Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol. 2002;20(6):753-760.
36. Adiguzel O, Kaptanoglu E, Turgut B, et al. The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: a prospective study with semiquantitative SPECT. South Med J. 2004;97:651-655.
37. Wood PB, Patterson JC 2nd, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain. 2007;8(1):51-58.
38. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep. 2002;4:299-305.
39. Burckhardt DC, Goldenberg D, Crofford L, et al. Guideline for the management of fibromyalgia syndrome pain in adults and children. In: APS Clinical Practice Guidelines Series. No 4. Glenview, IL: American Pain Society; 2005.
40. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536-541.
41. Lawson K. Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatr Dis Treat. 2008;4(6):1059-1071.
42. Maurizio SJ, Rogers JL. Recognizing and treating fibromyalgia. Nurse Pract. 1997;22:18-33.
43. Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis. A doubleblind, placebo-controlled study. Arthritis Rheum. 1986;29:655-659.
44. Bennett RM, Gatter RA, Campbell SM, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum. 1988;31:1535-1542.
45. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Care Res. 2004;51:9-13.
46. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29(11):1371-1377.
47. Goldenberg DL, Mayskiy M, Mossey C, Ruthazar R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852-1859.
48. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol. 2007;21(3):499-511.
49. Share NN, McFarlane CS. Cyclobenzaprine: a novel centrally acting skeletal muscle relaxant. Neuropharmacology. 1975;14(9):675-684.
50. Quimby LG, Gratwick GM, Whitney CD, Block SR. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl. 1989;19:140-143.
51. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994;23:255-259.
52. Arnold LM, Hess EV, Hudson JI, Berno SE, Keck PE. A randomized, placebo-controlled, double-blind, flexibledose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112:191-197.
53. Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292(19):2388-2395.
54. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61(3):445-449.
55. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia-a randomized, double-blind, placebo-controlled study. Eur J Pain. 2000;4:27-35.
56. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003;11:1561-1565.
57. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics. 1998;39:14-17.
58. Krell H, Cook IA, Abrams M, et al. Reboxetine yields symptomatic and functional improvement in unipolar depression. Scottsdale, AZ: Poster abstracts from the 41st Annual Meeting of the National Institutes of Mental Health's New Clinical Drug Evaluation Unit; 2001.
59. Wood PB, Schweinhardt P, Jaeger E, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci. 2007;25: 3576-3582.
60. Palangio M, Flores JA, Joyal SV. Treatment of fibromyalgia with sibutramine hydrochloride monohydrate. Arthritis Rheum. 2002;46:2545-2546.
61. Lawson K. Pharmacological treatments of fibromyalgia: do complex conditions need complex therapies? Drug Discov Today. 2008;13(7-8): 333-340.
62. Holman AJ, Myers RR. A randomized, double-blind, placebocontrolled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;52:2495-2505.
63. Arnold LM. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther. 2006;8(4):212.
64. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg. 2003;97:1730-1739.
65. Nikolajsen L, Gottrup H, Kristensen AGD, Jensen TS. Memantine (a N-methyl-Daspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg. 2000;91:960-966.
66. Weinbroum AA, Rudick V, Paret G, Ben-Abraham R. The role of dextromethorphan in pain control. Can J Anaesth. 2000;47:585-596.
67. Kim SH, Jang TJ, Moon IS. Increased expression of N-methyl-Daspartate receptor subunit 2D in the skin of patients with fibromyalgia. J Rheumatol. 2006;33:785-788.
68. Recla JM, Sarantopoulos CD. Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy? Med Hypotheses. 2009;73(2):177-183.
69. Khojainova N, Santiago-Palma J, Kornick C, Breitbart W, Gonzales GR. Olanzapine in the management of cancer pain. J Pain Symptom Manage. 2002;23:346-350.
70. Silberstein SD, Peres MFP, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache. 2002;42:515-518.
71. Gorski ED, Willis KC. Report of three case studies with olanzapine for chronic pain. J Pain. 2003;4:166-168.
72. Kiser R, Cohen HM, Freedenfeld RN, Jewell C, Fuchs PN. Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Manage. 2001;22:704-708.
73. Freedenfeld RN, Murray M, Fuchs PN, Kiser RS. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. Pain Pract. 2006;6(2):112-118.
74. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(9):6-12.
75. Calandre EP, Hidalgo J, Rico-Villademoros F. Use of ziprasidone in patients with fibromyalgia: a case series. Rheumatol Int. 2007;5:473-476.
76. Errington AC, Coyne L, Stöhr T, Selve N, Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology. 2006;50:1016-1029.
77. Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73:157-169.
78. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res. 2007;73:1-52.
79. US National Institutes of Health. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/. Accessed on October 10, 2009.
80. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009;61(2):197-216.
81. Corchero J, Manzanares J, Fuentes JA. Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol. 2004;16:159-172.
82. Salio C, Fischer J, Franzoni MF, Mackie K, Kaneko T, Conrath M. CB1-canabinoid and mu-receptor co-localization on postsynaptic target in the rat dorsal horn. NeuroReport. 2001;12:3689-3692.
83. Burstein S, Levin E, Varanelli C. Prostoglandins and cannabis, II: Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochem Pharmacol. 1973;22:2905-2910.
84. Evans FJ. Cannabinoids: The separation of central from peripheral effects on a structural basis. Planta Med. 1991;57:S60-S67.
85. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164-173.
86. Wiegant VM, Sweep CG, Nir I. Effect of acute administration of delta 1-tetrahydrocannabinol on beta-endorphin levels in plasma and brain tissue of the rat. Experientia. 1987;43:413-415.
87. Mailleux P, Vanderhaeghen JJ. Delta-9-tetrahydrocannabinol regulates substance P and enkephalin mRNAs levels in the caudate-putamen. Eur J Pharmacol. 1994;267:R1-R3.
88. Ko G, Wine W. Chronic pain and cannabinoids: A survey study of current fibromyalgia treatment approaches together with an overview and case studies of a new "old" treatment approach. Pract Pain Manage. 2005:1-8.
89. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66: 355-474.
90. 2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28:75-82.
91. Kranzler J, Gendreau J, Rao S. The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull. 2002;36:165-213.
92. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebocontrolled, multicenter trial. Arthritis Rheum. 2007;56:1336-1344.
93. Crofford LJ. Pain management in fibromyalgia. Curr Opin Rheumatol. 2008;20(3):246-250.
94. Farber L, Stratz T, Bruckle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia- a highly selective and competitive 5-HT3 receptor antagonist. Scand J Rheumatol. 2000;113:49-54.
95. Stratz T, Muller W. The use of 5-HT3 receptor antagonists in various rheumatic diseases-a clue to the mechanism of action of these agents in fibromyalgia? Scand J Rheumatol. 2000;113:66-71.
96. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev. 2007;4:CD003960.
97. Reitblat T, Zamir D, Polishchuck I, Novochatko G, Malnick S, Kalichman L. Patients treated by tegaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study. Clin Rheumatol. 2009;28(9):1079-1082.
98. Pardi D, Black J. Gamma-hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. CNS Drugs. 2006;20:993-1018.
99. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol. 2003;30:1070-1074.
100. Sarzi-Puttini P, Buskila D, Carrabba M, Doria A, Atzeni F. Treatment strategy in fibromyalgia syndrome: where are we now? Semin Arthritis Rheum. 2008;37(6):353-365.
101. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry. 2005;66(9):31-41.
102. Schwartz T, Rayancha S, Rashid A, Chlebowksi S, Chilton M, Morel M. Modafinil treatment for fatigue associated with fibromyalgia (concise reports) J Clin Rheumatol. 2007;13:52.
103. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-methylphenilate- and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A. 1996;93:14128-14133.
104. Pachas WN. Modafinil for the treatment of fatigue of fibromyalgia. J Clin Rheumatol. 2003;9(4):282-285.
105. Glass JM. Fibromyalgia and cognition. J Clin Psychiatry. 2008;69(2):20-24.
106. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM. Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol. 1997;24:1384-1389.
107. Leal-Cerro A, Povedano J, Astorga R, et al. The growth hormone (GH)-releasing hormone-GH-insulin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab. 1999;84:3378-3381.
108. Cuneo RC, Salomon F, McGauley GA, Sönksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol. 1992;37:387-397.
109. Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol. 1991;70:695-700.
110. McGauley GA, Cuneo RC, Salomon F, Sönksen PH. Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Horm Res. 1990;33(Suppl 4):52-54.
111. Bennett RM. The contribution of muscle to the generation of fibromyalgia symptomatology. J Musculoskel Pain. 1996;4:35-59.
112. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med. 1998;104(3):227-231.
113. Harati Y, Gooch C, Swenson M, et al. Maintenance of the longterm effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications. 2000;14:65-70.
114. Russell IJ, Kamin M, Bennett RM, et al. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol. 2000;6:250-257.
115. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992;260:275-285.
116. Bennett RM, et al. impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;53:519-527.
117. Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol. 1985;12:980-983.
118. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29:1371-1377.
119. Ur E, Serri O, Legg K, Murphy LJ, Ezzat S. Canadian guidelines for the management of adult growth hormone deficiency. Clin Invest Med. 2006;29:83-90.
120. Paiva ES, Deodhar A, Jones KD, Bennett R. Impaired growth hormone secretion in fibromyalgia patients: evidence for augmented hypothalamic somatostatin tone. Arthritis Rheum. 2002;46:1344-1350.
121. Jones KD, Burckhardt CS, Deodhar AA, Perrin NA, Hanson GC, Bennett RM. A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. Arthritis Rheum. 2008;58(2):612-622.
122. Acuña-Castroviejo D, Escames G, Macias M, et al. Cell protective role of melatonin in the brain. J Pineal Res. 1995;19:57-63.
123. Khaldy H, León J, Escames G, et al. Circadian rhythm of dopamine and their metabolites in mouse striatum: effects of pinealectomy and melatonin replacement. Neuroendocrinology. 2002;75: 201-208.
124. Acuña-Castroviejo D, Escames G, López LC, Hitos AB, León J. Melatonin and nitric oxide: two required antagonists for mitochondrial homeostasis. Endocrine. 2005;27(2):159-168.
125. Almay BG, Von Knorring L, Wetterberg L. Melatonin in serum and urine in patients with idiopathic pain syndromes. Psychiatr Res. 1987;22:179-191.
126. Acuna-Castroviejo D, Escames G, Reiter RJ. Melatonin therapy in fibromyalgia. J Pineal Res. 2006;40(1):98-99.
127. FDA Center for Drug Evaluation and Research. Savella (milnacipran) label information. January 8, 2009. Available from: http://www.fda. gov/cder/foi/label/2009. Accessed on October 10, 2009.
128. Boomershine CS. First pregabalin and now duloxetine for fibromyalgia syndrome: closer to a brave new world? Nat Clin Pract Rheumatol. 2008;4:636-637.
129. Boomershine CS, Crofford LJ. A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol. 2009;5(4):191-199.
130. Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007;105:1805-1015.
131. Vera-Llonch M, Dukes E, Argoff C, Oster G. Analgesic outcomes in patients with painful diabetic neuropathy or post-herpetic neuralgia receiving pregabalin versus gabapentin. J Pain. 2005;6:S33.
132. Crofford LJ, Rowbotham MD, Mease PJ, et al. Pregabalin for the treatment of fibromylagia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264-1273.
133. Arnold L, Russell I, Diri E, et al. A 14-week, randomized, doubleblinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9(9):792-805.
134. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419-431.
135. Zareba G. New treatment options in the management of fibromyalgia: role of pregabalin. Neuropsychiatr Dis Treat. 2008;4(6):1193-1201.
136. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974-2984.
137. Arnold LM, Pritchett YL, D'Souza DN, et al. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebocontrolled clinical trials. J Womens Health (Larchmt). 2007;16:1145-1156.
138. Gendreau RM, Mease PJ, Rao SR, Kranzler JD, Clauw DJ. Milnacipran: a potential new treatment of fibromyalgia. Arthritis Rheum. 2003;48:S616.
139. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10:732-747.
140. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebocontrolled, multiple-dose clinical trial. Clin Ther. 2008;30:1988-2004.
141. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebocontrolled trial. J Rheumatol. 2009;36:398-409.
142. Bennett RM. Fibromyalgia: a new treatment option for fibromyalgia. Nat Rev Rheumatol. 2009;5(4):188-190.
143. Forseth K∅, Gran JT. Management of fibromyalgia: what are the best treatment choices? Drugs. 2002;62(4):577-592.
144. Gam AN, Warming S, Larsen LH, et al. Treatment of myofascial trigger points with ultrasound combined with massage and exercise-a randomized controlled trial. Pain. 1998;77(1):73-79.
145. Lehmann J, Delateur B, Warren C, Stonebridge J. Heating of joint structures by ultrasound. Arch Phys Med Rehabil. 1968;49(1): 28-30.
146. Gur A. Physical therapy modalities in management of fibromyalgia. Curr Pharm Des. 2006;12(1):29-35.
147. Almeida TF, Roizenblatt S, Benedito-Silva AA, Tufik S. The effect of combined therapy (ultrasound and interferential current) on pain and sleep in fibromyalgia. Pain. 2003;104(3):665-672.
148. Wassselmann U, Lin SF, Rymer WZ. Selective decrease of small sensory neurons in lumbar dorsal root ganglia labeled with horseradish peroxidase after ND: YAG laser irradiation of the tibial nerve in the rat. Exp Neurol. 1991;111(2):251-262.
149. Sattayut S, Hughes F, Bradley P. 820 nm Gallium Aluminium Arsenide laser modulation of a prostaglandin E2 production in interleukin 1 stimulated myoblasts. Laser Ther. 1999;11(2):88-95.
150. Campana VR, Moya M, Gavotto A, Juri H. The relative effects of He-Ne laser and meloxicam on experimentally induced inflammation. Laser Ther. 1999;11(1):36-42.
151. Nishida J, Satoh T, Satodate R. Histological evaluation of the effect of He Ne laser irradiation an the synovial membrane in rheumatoid arthritis. Japanese J Rheumatol. 1990;2:251-260.
152. Siebert W, Seichert N, Siebert B, Wirth CJ. What is the efficacy of soft and mid lasers in therapy of tendinopathies? A double-blind study. Arch Orthop Trauma Surg. 1987;106(6):358-363.
153. Olavi A, Pekka R, Pertti K, Pekka P. Effects of the infrared laser therapy at treated and non-treated trigger points. Acupunct Electrother Res. 1989;14(1):9-14.
154. Laasko EL, Cramond T, Richardson C, Galligan JP. Plasma ACTH and β-endorphin levels in response to low level laser therapy for myofascial trigger points. Laser Ther. 1994;6(3):133-142.
155. Pioro-Boisset M, Esdaile JM, Fitzcharles M. Alternative medicine use in f ibromyalgia syndrome. Arthritis Care Res. 1996;9(1): 13-17.
156. Gur A, Karakoç M, Nas K, Çevik R, Saraç AJ, Demir E. Efficacy of low power laser therapy in fibromiyalgia: a single-blind, placebo-controlled trial. Lasers Med Sci. 2002;17:57-61.
157. Gur A, Karakoç M, Nas K, Çevik R, Saraç AJ, Ataog?lu S. Effects of low power laser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebo-controlled trial. Rheumatol Int. 2002;22: 188-193.
158. Mannerkorpi K, Burckhardt CS, Bjelle A. Physical performance characteristics of women with fibromyalgia. Arthritis Care Res. 1994;7:123-129.
159. Bengtsson A, Henriksson KG, Larsson J. Muscle biopsy in primary fibromyalgia: light microscopical and histochemical findings. Scand J Rheumatol. 1986;15:1-6.
160. McCain GA, Bell DA, Mai FM, Halliday PD. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum. 1988;31:1135-1141.
161. Nichols DS, Glenn TM. Effects of aerobic exercise on pain perception, affect, and level of disability in individuals with fibromyalgia. Phys Ther. 1994;74:327-332.
162. McCain G, Bell D, Mai F, et al. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum. 1988;31(9): 1135-1141.
163. Martin L, Nutting A, MacIntosh BR, Edworthy SM, Butterwick D, Cook J. An exercise program in the treatment of fibromyalgia. J Rheumatol. 1996;23:1050-1053.
164. Lena Fortuna R, Friol González JE. Fibromialgia y Magnetoterapia. Revista Cubana de Reumatología. 2002;4(1):56.
165. Sueiro Blanco F, Estévez Schwarz I, Ayán C, Cancela J, Martín V. Potential benefits of non-pharmacological therapies in fibromyalgia. Open Rheumatol J. 2008;2:1-6.
166. Holdcraft LC, Assefi N, Buchwald D. Complementary and alternative medicine in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol. 2003;17:667-683.
167. Singh BB, Wu WS, Hwang SH, et al. Effectiveness of acupuncture in the treatment of fibromyalgia. Altern Ther Health Med. 2006; 12:34-41.
168. Rooks DS. Fibromyalgia treatment update. Curr Opin Rheumatol. 2007;19(2):111-117.
169. Assef i NP, Sherman KJ, Jacobsen C, Goldberg J, Smith WR, Buchwald D. A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia. Ann Intern Med. 2005; 143(1):10-19.
170. Jain KK. Physical, physiological, and biochemical aspects of hyperbaric oxygenation. In: Jain KK, Neubauer R, Correa JG, Camporesi EM, editors. Textbook of Hyperbaric Medicine, 2nd ed. Seattle, WA: Hogrefe and Huber Publishers; 1996. p. 11-26.
171. Yildiz S, Kiralp MZ, Akin A, et al. A new treatment modality for fibromyalgia syndrome: hyperbaric oxygen therapy. J Int Med Res. 2004;32(3):263-267.
172. Curkovic B, Vitulic V, Babic-Naglic D, Durrigl T. The influence of heat and cold on the pain threshold in rheumatoid arthritis. Z Rheumatol. 1993;52:289-291.
173. Lehmann JE. Diathermy and superficial heat, laser and cold therapy. In: Kottke EJ, Lehmann JE, editors. Krusen's Handbook of Physical Medicine and Rehabilitation. Philadelphia, PA: Saunders; 1990.
174. Cimbiz A, Bayazit V, Hasan Hallaceli H, Ugur Cavlak U. The effect of combined therapy (spa and physical therapy) on pain in various chronic diseases. Complement Ther Med. 2005;13:244-250.
175. Buskila D, Abu-Shakra M, Neumann L, et al. Balneotherapy for fibromyalgia at the Dead Sea. Rheumatol Int. 2001;20:105-108.
176. Crofford LJ, Appleton BE. Complementary and alternative therapies for fibromyalgia. Curr Rheumatol Rep. 2001;3:147-156.
177. Adams N, Sim J. Rehabilitation approaches in fibromyalgia. Disabil Rehabil. 2005;27(12):711-723.
178. Gamber RG, Shores JH, Russo DP, Jimenez C, Rubin BR. Osteopathic manipulative treatment in conjunction with medication relieves pain associated with fibromyalgia syndrome: Results of a randomized clinical pilot project. J Am Osteopath Assoc. 2002;102:321-325.
179. Pioro-Boisset M, Esdaile JM, Fitzcharles M. Alternative medicine use in fibromyalgia syndrome. Arthritis Care Res. 1996;9(1):13-17.
180. Keefe FJ, Caldwell DS. Cognitive behavioral control of arthritis pain. Med Clin North Am. 1997;81:277-290.
181. Morley S, Eccleston C, Williams A. Systematic review and metaanalysis of randomized controlled of cognitive behavior therapy and behavioral therapy for chronic pain in adults, excluding headache. Pain. 1999;80(1-2):1-13.
182. Vlaeyen JW, Teeken-Gruben NJ, Goossens ME, et al. Cognitiveeducational treatment of fibromyalgia: a randomized clinical trial. I. Clinical effects. J Rheumatol. 1996;23:1237-1245.
183. Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol. 1991;20:294-302.
184. Ammer K, Melnizky P. Medicinal baths for treatment of generalized fibromyalgia. Forsch Komplementarmed. 1999;6:80-85.
185. Abraham GE, Flechas ID. Management of fibromyalgia: a rationale for the use of magnesium and malic acid. J Nutr Med. 1992;3:49-59.
186. Merchant RE, Carmack CA, Wise CM. Nutritional supplementation with chlorella pyrenoidosa for patients with fibromyalgia syndrome: a pilot study. Phytother Res. 2000;14:167-173.
187. Merchant RE, Andre C. A review of recent clinical trials of the nutritional supplement Chlorella pyrenoidosa in the treatment of fibromyalgia, hypertension, and ulcerative colitis. Altern Ther Health Med. 2001;7:79-91.
188. Holdcraft LC, Assefi N, Buchwald D. Complementary and alternative medicine in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol. 2003;17(4):667-683.
189. Thimineur M, De Ridder D. C2 area neurostimulation: a surgical treatment for fibromyalgia. Pain Med. 2007;8(8):639-646.